MarketMoodz
Novo Nordisk to cut U.S. Wegovy, Ozempic, Rybelsus price to $675 in 2027
Novo Nordisk will slash the U.S. list prices for Wegovy, Ozempic, and Rybelsus by up to 50% to $675 per month, effective January 1, 2027. The move targets insured patients whose cost-sharing is tied to list prices, aiming to ease access amid payer pressure. Novo Nordisk has not publicly confirmed the plan beyond CNBC's coverage.
Key Takeaways
- New list price for Wegovy, Ozempic, and Rybelsus set at $675/month starting Jan 1, 2027.
- Current list prices run about $1,350/month for Wegovy and $1,027/month for Ozempic/Rybelsus.
- Price cuts target patients with insurance tied to list prices and higher-deductible plans.
- Eli Lilly remains the dominant GLP-1 player with limited price cuts to date.
- Payer pressure and calls for lower access underpin the move and market context
People Involved
- Jamey Millar Novo Nordisk Head of U.S. Operations
Entities Involved
- Novo Nordisk A/S Danish pharmaceutical company issuing GLP-1 therapies
- Eli Lilly and Company Major GLP-1 competitor in the U.S. market
MarketMoodz Analysis
For investors, the price reset could lift demand if accessibility expands among insured patients, but it also compresses per-unit margins. The shift may reallocate value from price to volume and could pressure peers to respond in kind, especially if payer negotiations harden around list prices.
Historically, GLP-1 therapies have traded with high list prices and evolving coverage terms in the U.S. The move places Novo Nordisk in a strategic position ahead of broader pricing scrutiny and payer-led access initiatives, potentially reshaping market expectations for Novo and Lilly.
Watch next for eventual Novo Nordisk confirmation of the plan, any subsequent pricing adjustments by Lilly, and how payers adjust formularies and patient cost-sharing as 2027 approaches.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial